This page is maintained. Prices are re-read at source and dated; evidence is checked against the published trial. Newest across the site: news · journal · corrections.
Last medically reviewed: · This page is informational and does not constitute medical advice.
A publication that never corrects itself is not more accurate than one that does — it is less observable. Every correction is listed here in full, with what we said, what is correct and why it mattered.
Corrections are published at the same prominence as the original claim, and the affected pages carry the correction inline rather than being edited silently.
· COR-005 · Material — provider inclusions
NexLife rows and the NexLife review
What we said: We listed “laboratory review” among NexLife’s inclusions, said its pharmacy network could include Hallandale, Empower, Absolute, DiRx and Red Rock, and called NexLife the lowest verified all-inclusive price.
What is correct: NexLife’s plan pages, read October 15, 2026, list provider review, a nutrition plan, a coaching call, 24/7 support and free shipping, and do not say lab work is included. They name three 503A pharmacies: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA). Eden’s flat $129 and $99 a month are lower than NexLife at every plan length, so NexLife is now described as our editor’s pick, not the lowest price.
Why it mattered: An inclusion a provider does not state, or a superlative our own table contradicts, is the kind of claim this site exists to catch.
· COR-004 · Material — regulatory status
Peptide pages, the glossary and COR-002 below
What we said: We said BPC-157 is on FDA’s 503A Category 2 list, including in COR-002.
What is correct: FDA moved BPC-157, TB-500 and other peptides out of Category 2 in April 2026 after their nominations were withdrawn (FDA safety-risks page, current April 22, 2026). They now sit in a “nominated but withdrawn” table. They are not on the 503A bulks list or in Category 1, so the practical conclusion, that a 503A pharmacy has no lawful route to compound them, still holds as of October 15, 2026.
Why it mattered: The label was wrong even though the conclusion was right, and a reader checking FDA’s table would have found the discrepancy. Full status: October 2026 report.
· COR-001 · Material — starter price quoted as the price of treatment
Every page quoting the approved oral semaglutide price
What we said: We described the approved oral semaglutide tablet as $149 a month without stating which doses that covers.
What is correct: The manufacturer's own price guide, read 4 August 2026, sets $149 for the 1.5 mg and 4 mg doses and $299 for the 9 mg and 25 mg maintenance doses. The $149 rate on 4 mg ends 31 August 2026, after which it becomes $199.
Why it mattered: Quoting a starter-dose figure as the price of treatment is the exact error we document in provider marketing. Every affected page now carries the full ladder.
· COR-002 · Material — availability
Peptide pages referencing BPC-157 [superseded by COR-004]
What we said: BPC-157 was described alongside peptides available through compounding pharmacies without stating its regulatory status.
What is correct: BPC-157 is on the FDA's 503A Category 2 bulk drug substances list, which identifies substances raising significant safety risks that may not be used in compounding. It has no human efficacy trials.
Why it mattered: A reader comparing peptides needs to know which ones a legitimate pharmacy cannot legally compound. Omitting it made the list look like a menu.
What we said: Trial figures appeared on pages about compounded preparations without a consistent statement that the trials studied the approved product.
What is correct: Every efficacy figure on this site was collected on an FDA-approved product. No compounded preparation has a trial of its own, and no figure transfers to one.
Why it mattered: A number placed beside a product implies it describes that product.
How to report an error
Email the research desk with the page and the figure you believe is wrong. We would rather a figure be found and corrected than repeated. Response commitment and escalation route: the methodology.